1458653-20-7

Basic information

• Product Name: 3-(4-bromo-3,5-dimethyl-phenoxymethyl)azetidine-1-carboxylic acid tert-butyl ester
• Synonyms: 3-(4-bromo-3,5-dimethyl-phenoxymethyl)azetidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1458653-20-7
• Molecular Weight: 370.286
• Mol File: 1458653-20-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(4-bromo-3,5-dimethyl-phenoxymethyl)azetidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-bromo-3,5-dimethyl-phenoxymethyl)azetidine-1-carboxylic acid tert-butyl ester(1458653-20-7)
• EPA Substance Registry System: 3-(4-bromo-3,5-dimethyl-phenoxymethyl)azetidine-1-carboxylic acid tert-butyl ester(1458653-20-7)

Safety Data

• Hazardous Substances Data: 1458653-20-7(Hazardous Substances Data)

Upstream product

• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 142253-56-3 3-hydroxymethyl-azetidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1458653-21-8 3-((4-bromo-3,5-dimethylphenoxy)methyl)-1-(methylsulfonyl)azetidine 
• 1458653-19-4 3-((4-bromo-3,5-dimethylphenoxy)methyl)azetidine 

Relevant articles and documents

INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.